| 0.1942 -0.009 (-4.34%) | 12-08 15:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.24 | 1-year : | 0.28 |
| Resists | First : | 0.2 | Second : | 0.24 |
| Pivot price | 0.18  |
|||
| Supports | First : | 0.16 |
Second : | 0.14 |
| MAs | MA(5) : | 0.19 |
MA(20) : | 0.18 |
| MA(100) : | 0.21 |
MA(250) : | 0.34 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 79.2 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 1.3 | Low : | 0.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AMTI ] has closed below upper band by 35.0%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.2 - 0.2 | 0.2 - 0.2 |
| Low: | 0.17 - 0.17 | 0.17 - 0.18 |
| Close: | 0.19 - 0.19 | 0.19 - 0.2 |
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Tue, 28 Nov 2023
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana : Kahn Swick & Foti, LLC ... - Marketscreener.com
Tue, 28 Nov 2023
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Wed, 22 Nov 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHS, AMTI, ESMT, CNSL - GlobeNewswire
Thu, 09 Nov 2023
Applied Molecular Transport Reports Third Quarter 2023 Financial Results - Yahoo Finance
Tue, 03 Oct 2023
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept ... - GlobeNewswire
Mon, 25 Sep 2023
This biotech went public 3 years ago at $14 per share. Here's how its stock cratered to 27 cents - San Francisco ... - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 21.9 (%) |
| Held by Institutions | 44.5 (%) |
| Shares Short | 391 (K) |
| Shares Short P.Month | 524 (K) |
| EPS | -1.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.3 % |
| Return on Equity (ttm) | -158.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.48 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|